March 16, 2021 | HealthClot

Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung …

By HealthClot Moderator
March 16, 2021
0

Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung … Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in The Journal of Molecular Diagnosis, published by Elsevier, investigators provide for […]

Covid: Charities warn cancer death rate could rise

By HealthClot Moderator
March 16, 2021
0

Covid: Charities warn cancer death rate could rise Contributors A group of 47 cancer charities says that without urgent action, the UK’s cancer death rate will rise for the first time in decades. NHS figures suggest tens of thousands fewer people started cancer treatment since the first lockdown compared to normal times. One Cancer Voice […]

Psycho-oncology: A lesser known trump card in cancer care

By HealthClot Moderator
March 16, 2021
0

Psycho-oncology: A lesser known trump card in cancer care Express News Service KOCHI: Cancer is often an uninvited guest in our lives. It takes insurmountable courage to face such a diagnosis which can be devastating for many people. Yet, we often fail to recognise the other important aspects of the struggle a part from medical intervention. […]

NCCN Updates Clinical Practice Guideline for Multiple Myeloma

By HealthClot Moderator
March 16, 2021
0

NCCN Updates Clinical Practice Guideline for Multiple Myeloma On March 15, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for multiple myeloma. In the section for therapy for previously treated multiple myeloma, under other regimens, melphalan flufenamide/dexamethasone was added as a category 2A recommendation.—Janelle Bradley Published at Tue, […]

By HealthClot Moderator
March 16, 2021
0

Zacks: Analysts Expect Fate Therapeutics, Inc. (NASDAQ:FATE) Will Post Quarterly Sales of $7.07 … Wall Street analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $7.07 million in sales for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Fate Therapeutics’ earnings. The lowest sales estimate is $5.00 million and the […]